Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.

Oncotarget - 22 Sept 2015

Zhang Zhen-Yu, Chan Aden Ka-Yin, Ding Xiao-Jie, Qin Zhi-Yong, Hong Christopher S, Chen Ling-Chao, Zhang Xin, Zhao Fang-Ping, Wang Yin, Wang Yang, Zhou Liang-Fu, Zhuang Zhengping, Ng Ho-Keung, Yan Hai, Yao Yu, Mao Ying

Abstract excerpt

IDH mutations frequently occur in WHO grade II and III diffuse gliomas and have favorable prognosis compared to wild-type tumors. However, whether IDH mutations in WHO grade II and II diffuse gliomas predict enhanced sensitivity to adjuvant radiation (RT) or chemotherapy (CHT) is still being debated. Recent studies have identified recurrent mutations in the promoter region of telomerase reverse transcriptase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Kaplan-Meier Estimate

Share to Multivariate Analysis

Share to Neoplasm Grading

Share to Telomerase

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 26314843
DOI: 10.18632/oncotarget.4549
PMCID: PMC4694799

Genes

TERT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.PMID 26314843Read ↗

Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.Semantic proximity Read ↗

Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.Semantic proximity Read ↗

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.Semantic proximity Read ↗

Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas.Semantic proximity Read ↗

Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.Semantic proximity Read ↗

Prognostic Impact of TERT Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021 CriteriaSemantic proximity Read ↗

The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.Semantic proximity Read ↗

The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas.Semantic proximity Read ↗

TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.Semantic proximity Read ↗

TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.Semantic proximity Read ↗

Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.Semantic proximity Read ↗

TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.